Trials / Withdrawn
WithdrawnNCT00557791
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
A Phase 3, Randomized, Double-masked, Parallel-assignment and Dose-finding Study of Intravitreal Bevasiranib Sodium, Administered Every 8 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effectiveness of three doses of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with three doses of Lucentis®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevasiranib | Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks |
| DRUG | ranibizumab | Lucentis® (0.5 mg) administered intravitreally every 4 weeks. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-07-01
- Completion
- 2012-07-01
- First posted
- 2007-11-14
- Last updated
- 2015-03-06
Source: ClinicalTrials.gov record NCT00557791. Inclusion in this directory is not an endorsement.